Država: Južnoafrička Republika
Jezik: engleski
Izvor: South African Health Products Regulatory Authority (SAHPRA)
Donmed
REMERON® 15 mg TABLETS REMERON® 30 mg TABLETS 34346.102 RU M1060.052.105 SCHEDULING STATUS S5 PROPRIETARY NAME (and dosage form): REMERON ® 15 mg TABLETS REMERON ® 30 mg TABLETS COMPOSITION Each Remeron 15 mgtablet contains 15 mg of mirtazapine . Each Remeron 30 mg tablet contains 30 mg of mirtazapine. PHARMACOLOGICAL CLASSIFICATION A/1.2/Psychoanaleptics (antidepressants) PHARMACOLOGICAL ACTION Pharmacodynamic properties Mirtazapine is a tetracyclic antidepressant, belonging to the piperazino-azepine group of compounds. Mirtazapine is an antagonist of central alpha 2 -auto and hetero-adrenoceptors which causes an increase in both noradrenaline and serotonin release. The effect of released serotonin is exerted specifically via 5-HT 1 type receptors, because 5-HT 2 and 5-HT 3 type receptors are specifically blocked by mirtazapine. Both enantiomers of mirtazapine are presumed to contribute to the antidepressant activity, the S(+) enantiomer by blocking alpha 2- auto and hetero-adrenoceptors and 5-HT 2 receptors and the R(-) enantiomer by blocking alpha 2 hetero-adrenoceptors and 5-HT 3 receptors. In one study there was no efficacy difference indicated between the two enantiomers, despite their different receptor affinities. The potent histamine H 1 -antagonistic activity of mirtazapine is responsible for its sedative properties. Mirtazapine has modest antagonism on cholinergic activity. Mirtazapine has modest peripheral alpha 1 -adrenergic antagonist activities and has been associated with acute postural hypotension in healthy volunteer studies but less so in patient studies (see “Side-effects”). Pharmacokinetic properties After oral administration of Remeron tablets, the active constituent mirtazapine is rapidly and well-absorbed (bioavailability ~50%), reaching peak plasma levels a Pročitajte cijeli dokument